Parabilis Medicines key facts
as of Oct 2026- Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them.
- Parabilis Medicines is valued at approximately $920.0M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $812.0M across 3 recorded rounds; the latest was Later Stage VC (Series F) ($305.0M) in Jan 2026.
- Notable investors include General Catalyst, Fidelity Management & Research Company, RA Capital Management, GV, ARCH Venture Partners — 38 tracked in total.
- 4 institutional filers report fund marks on Parabilis Medicines across 27 filings.
- Status: Privately Held (backing).
Institutions disagree (3 filers, 36% apart) — shown at its later-stage round, Jan 2026 ($920.0M post-money).
- ·The complete investor list: 38 names
- ·Watch Parabilis Medicines: the Monday email on marks, rounds and moves
Institutional fund marks on Parabilis Medicines
4 filers · latest Jul 20264 SEC-registered funds reported 27 fair-value marks on Parabilis Medicines between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Parabilis Medicines funding rounds
3 roundsWho backs Parabilis Medicines
38+Parabilis Medicines valuation
Parabilis Medicines is valued at approximately $920 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its later-stage round in Jan 2026, at a $920 million post-money valuation.
Recent activity
In the last 90 days, Parabilis Medicines's record added 8 institutional fund marks (latest period Jul 2026).
How much has Parabilis Medicines raised?
Parabilis Medicines has raised $812 million across 3 recorded rounds since 2022. The largest was a $305 million Series F in Jan 2026.
Institutional holders and vehicles
4 SEC-registered funds reported 27 fair-value marks on Parabilis Medicines between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Parabilis Medicines investors
38 investors are on record for Parabilis Medicines, including General Catalyst, Fidelity Management & Research Company, RA Capital Management and GV. By type, the record holds 14 venture capital firms, 3 hedge funds and 2 private equity firms. The Series F in Jan 2026 drew 21 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Neurona Therapeutics ($1.1 billion), Bluejay Therapeutics ($820 million) and Abcuro ($700 million).
About Parabilis Medicines
Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them. The company develops a pipeline of ultra-tunable peptide therapeutics based on a proprietary platform that is engineered to modulate previously inaccessible biological targets, incorporates structure-guided design to optimize pharmacologic properties, and supports programs primarily in oncology and other indications, enabling biopharmaceutical researchers and healthcare providers to access alternative treatment options for patients with limited effective therapies.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2015
- Employees
- 176
- Website
- parabilismed.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.